The Cooper Companies, Inc. (NASDAQ: COO): Comprehensive Corporate Profile & Financial Analysis
Source: The Cooper Companies, Inc. Form 10-K for the Fiscal Year Ended October 31, 2025
The Cooper Companies, Inc. (Cooper, we, or the Company) is a leading global medical device company dedicated to helping people experience life’s beautiful moments. Headquartered in San Ramon, California, Cooper sells its products in over 130 countries and positively impacts over fifty million lives each year.
- Coopervision: Segment revenue: $2.74 B (67.09%).
- Coopersurgical: Segment revenue: $1.35 B (32.97%).
📋 Quick Facts / Company Snapshot: The Cooper Companies, Inc.
| Attribute | Corporate Disclosure |
|---|---|
| Official Name | The Cooper Companies, Inc. |
| Ticker Symbol | COO |
| Primary Exchange | Nasdaq Global Select Market |
| Principal Executive Offices | 6101 Bollinger Canyon Road, Suite 500, San Ramon, California 94583 |
| Industry / Sector | Medical Device / Healthcare |
| Founded | 1990 (CooperSurgical inception) / Incorporated in Delaware |
| Total Employees | More than 15,000 employees globally (52% Americas, 42% EMEA, 6% Asia Pacific) |
| Key Locations | Americas, EMEA, and Asia Pacific (operating in over 130 countries) |
| Patents & Intellectual Property | Extensive portfolio of patents, trademark registrations, trade secrets, licenses, and technical know-how covering contact lens designs, materials, manufacturing processes, and specialized medical procedures |
| Principal Subsidiaries | CooperVision, Inc., CooperSurgical, Inc., CooperVision International Limited, CooperSurgical Netherlands B.V., CooperVision Holding Kft. |
| Parent Company | None (Independent Publicly Traded Company) |
| Chief Executive Officer | Al White (President and Chief Executive Officer) |
| Chief Financial Officer | Brian Andrews (Executive Vice President and Chief Financial Officer) |
| External Website | https://www.coopercos.com |
1. Corporate Identity: The Cooper Companies, Inc. Overview & History
The Big Picture
The Cooper Companies, Inc. (Cooper, we, or the Company) is a leading global medical device company dedicated to helping people experience life’s beautiful moments. Headquartered in San Ramon, California, Cooper sells its products in over 130 countries and positively impacts over fifty million lives each year. Through relentless dedication to clinical excellence, product quality, and technological innovation, the enterprise has established itself as an indispensable partner for healthcare professionals, eye care practitioners, hospitals, surgical centers, and fertility clinics worldwide.
Cooper operates through two primary business segments: CooperVision and CooperSurgical. Each segment elevates standards of care within its respective field—vision correction, myopia management, fertility, and women’s health. The enterprise combines decentralized operational agility with centralized corporate oversight, ensuring consistent adherence to rigorous quality standards, regulatory compliance, and strategic capital allocation.
The Founders & Their Legacy
Since the inception of CooperSurgical in 1990, the organization has systematically built its market presence and distribution infrastructure through a balanced strategy combining organic product development and selective, accretive acquisitions. Management has continually identified emerging healthcare needs, cultivated close working relationships with leading clinicians and researchers, and integrated complementary businesses into an efficient, unified operating model.
The Journey: History & Evolution
The historical evolution of The Cooper Companies reflects a steady transformation from a diversified healthcare enterprise into a focused, highly specialized medical device leader. Over the decades, CooperVision cemented its position as a global soft contact lens powerhouse by pioneering advanced silicone hydrogel materials such as Aquaform technology, expanding high-volume manufacturing capabilities across multiple continents, and introducing groundbreaking myopia management solutions. Concurrently, CooperSurgical expanded from a niche surgical instrument supplier into a diversified women’s health and fertility giant encompassing advanced medical devices, contraception, gamete and embryo cryostorage, donor services, and genetic testing laboratories.
The Corporate Umbrella
The corporate structure is anchored by two distinct operating divisions supported by centralized corporate functions. CooperVision focuses entirely on the global soft contact lens and myopia management market, addressing spherical, toric, and multifocal visual corrections across three primary geographic regions: the Americas, EMEA (Europe, Middle East, and Africa), and Asia Pacific. CooperSurgical focuses on fertility and women’s health, categorizing its offerings by the point of healthcare delivery: office and surgical products used in medical offices, ambulatory surgery centers, and hospitals primarily by OB/GYNs; and fertility products and services used primarily in specialized fertility clinics and assisted reproductive technology centers.
2. The Business Engine: The Cooper Companies, Inc. Business Model & Revenue Segments
The Core Divisions
| Segment | Net Sales (2025 in $ millions) | Net Sales (2024 in $ millions) | Latest YoY (%) |
|---|---|---|---|
| CooperVision | 2,743.8 | 2,609.4 | +5.15% |
| CooperSurgical | 1,348.6 | 1,286.0 | +4.87% |
CooperVision develops, manufactures, and markets a broad range of single-use, two-week, and monthly contact lenses featuring advanced optical designs and materials. CooperSurgical offers over 600 products and services spanning OB/GYN surgical devices, Paragard non-hormonal intrauterine devices, newborn stem cell cryostorage, in vitro fertilization (IVF) lab equipment and media, donor gametes, and genomic testing services.
The Global Product Catalog & Modalities
CooperVision competes in the worldwide soft contact lens market with two major product categories: toric and multifocal lenses (addressing astigmatism, myopia, and presbyopia); and spherical lenses (addressing near- and farsightedness), which include myopia management lenses. Wearing schedules—or modalities—include single-use daily disposable lenses and frequent replacement (FRP) lenses designed for two-week or monthly replacement.
Under the Biofinity brand, CooperVision markets monthly silicone hydrogel spherical (including Biofinity Energys), toric, multifocal, and toric multifocal lenses, representing its highest grossing product line. Two-week silicone hydrogel lenses are marketed under the Avaira Vitality brand. Single-use daily disposable silicone hydrogel lenses include the premium MyDay and MyDay Energys line, and the affordable clariti 1 day line, both offering spherical, toric, and multifocal options. Traditional hydrogel lenses are offered under the Proclear and Biomedics brands.
In myopia management, CooperVision features the MiSight 1 day lens (omafilcon A), which in November 2019 became the first and only product approved by the United States Food and Drug Administration (FDA) for slowing the progression of myopia in children aged 8-12 at the initiation of treatment. CooperVision subsequently secured approval for the MiSight 1 day lens from the Chinese National Medical Products Administration (NMPA) in August 2021 and from the Japanese Ministry of Health, Labour and Welfare (MHLW) in August 2025.
CooperSurgical’s office and surgical portfolio includes surgical instruments, labor and delivery tools, and Paragard, a hormone-free IUD offered exclusively in the United States that prevents pregnancy for up to ten years using copper as its sole active ingredient. CooperSurgical also provides newborn stem cell storage (cord blood and cord tissue) in the United States, Canada, and Australia. Its fertility portfolio encompasses IVF media, micro-tools, laboratory equipment, donor gametes, cryostorage, and comprehensive genomic services.
Mapping the Global Reach
| Geographic Region | CooperVision Net Sales (2025 in $ millions) | CooperVision Net Sales (2024 in $ millions) | Latest YoY (%) |
|---|---|---|---|
| Americas | 1,124.3 | 1,067.3 | +5.34% |
| EMEA | 1,064.4 | 988.3 | +7.70% |
| Asia Pacific | 555.1 | 553.8 | +0.23% |
International operations represent approximately half of total consolidated net sales. Products are sold in over 130 countries. The Company maintains robust distribution networks utilizing direct field sales representatives, specialized medical device distributors, optical chains, global retailers, and key account buying groups.
The Brick & Mortar Footprint
The enterprise maintains major manufacturing, distribution, research and development, and cryostorage facilities strategically positioned across the globe. CooperVision’s major manufacturing and distribution facilities are located in Costa Rica, Hungary, Puerto Rico, the United Kingdom, and the United States (including Arizona, New York, and California), with smaller facilities in Belgium, Spain, Canada, Japan, China, Australia, and other international hubs. CooperSurgical’s major manufacturing, cryostorage, and distribution facilities are located in Costa Rica, the Netherlands, the United Kingdom, and the United States (including Connecticut, New York, New Jersey, and Texas). Total leased square footage across the global real estate portfolio exceeds several million square feet, supporting executive offices, advanced manufacturing cleanrooms, specialized logistics warehouses, and clinical laboratories.
3. The Financial Health: The Cooper Companies, Inc. (FY 2025) Audited Financial Statements
Earnings, Expenses & Profits: The Cooper Companies, Inc. Income Statement
| Consolidated Statement of Income Line Items (in $ millions) | 2025 | 2024 | 2023 | Latest YoY (%) |
|---|---|---|---|---|
| Net sales | 4,092.4 | 3,895.4 | 3,593.2 | +5.06% |
| Cost of sales | 1,410.3 | 1,299.7 | 1,235.3 | +8.51% |
| Gross profit | 2,682.1 | 2,595.7 | 2,357.9 | +3.33% |
| Selling, general and administrative expense | 1,627.8 | 1,533.7 | 1,501.2 | +6.14% |
| Research and development expense | 172.2 | 155.1 | 137.4 | +11.03% |
| Amortization of intangibles | 199.2 | 201.2 | 186.2 | -0.99% |
| Operating income | 682.9 | 705.7 | 533.1 | -3.23% |
| Interest expense | 100.0 | 114.3 | 105.3 | -12.51% |
| Other expense | 16.4 | 9.1 | 14.9 | +80.22% |
| Income before income taxes | 566.5 | 582.3 | 412.9 | -2.71% |
| Provision for income taxes | 191.6 | 190.0 | 118.7 | +0.84% |
| Net income | 374.9 | 392.3 | 294.2 | -4.44% |
Net sales grew consistently across the three-year reporting window, reaching $4,092.4 million in fiscal 2025 compared to $3,895.4 million in fiscal 2024 and $3,593.2 million in fiscal 2023. This top-line expansion was driven by robust global demand for silicone hydrogel contact lenses, specialty toric and multifocal designs, myopia management products, and growth across CooperSurgical’s office, surgical, and fertility portfolios.
Assets, Debts & Equity: The Cooper Companies, Inc. Balance Sheet
| Consolidated Balance Sheet Line Items (in $ millions) | 2025 | 2024 | Latest YoY (%) |
|---|---|---|---|
| Cash and cash equivalents | 110.6 | 107.6 | +2.79% |
| Trade accounts receivable, net | 829.0 | 717.0 | +15.62% |
| Inventories | 846.0 | 802.7 | +5.39% |
| Prepaid expense and other current assets | 320.8 | 324.2 | -1.05% |
| Total current assets | 2,106.4 | 1,951.5 | +7.94% |
| Property, plant and equipment, net | 2,082.0 | 1,863.4 | +11.73% |
| Goodwill | 3,853.4 | 3,838.4 | +0.39% |
| Other intangibles, net | 1,586.3 | 1,791.0 | -11.43% |
| Deferred tax assets | 2,077.5 | 2,210.3 | -6.01% |
| Other assets | 689.2 | 660.6 | +4.33% |
| Total assets | 12,394.8 | 12,315.2 | +0.65% |
| Short-term debt | 47.8 | 33.3 | +43.54% |
| Accounts payable | 300.4 | 260.5 | +15.32% |
| Employee compensation and benefits | 210.6 | 174.8 | +20.48% |
| Deferred revenue | 127.9 | 129.9 | -1.54% |
| Other current liabilities | 426.1 | 424.3 | +0.42% |
| Total current liabilities | 1,112.8 | 1,022.8 | +8.80% |
| Long-term debt | 2,457.5 | 2,550.4 | -3.64% |
| Deferred tax liabilities | 93.3 | 96.0 | -2.81% |
| Long-term tax payable | 7.5 | 57.5 | -86.96% |
| Deferred revenue (non-current) | 201.8 | 193.3 | +4.40% |
| Other liabilities | 282.8 | 311.6 | -9.24% |
| Total liabilities | 4,155.7 | 4,231.6 | -1.79% |
| Stockholders’ equity | 8,239.1 | 8,083.6 | +1.92% |
Total assets stood at $12,394.8 million as of October 31, 2025, compared to $12,315.2 million as of October 31, 2024. The capital structure remains robust, backed by $8,239.1 million in total stockholders’ equity and disciplined management of long-term debt obligations under credit facilities.
Cash Flow & Capital Allocation: The Cooper Companies, Inc. Cash Flow Statement
| Consolidated Statement of Cash Flows Line Items (in $ millions) | 2025 | 2024 | 2023 | Latest YoY (%) |
|---|---|---|---|---|
| Net income | 374.9 | 392.3 | 294.2 | -4.44% |
| Depreciation and amortization | 377.4 | 375.1 | 367.7 | +0.61% |
| Share-based compensation expense | 70.5 | 75.1 | 62.1 | -6.13% |
| Non-cash operating lease expense | 45.6 | 38.7 | 40.0 | +17.83% |
| Other including asset impairment charges | 77.3 | 42.9 | 49.4 | +80.19% |
| Change in fair value of contingent consideration | — | — | (31.8) | N/M |
| Deferred income taxes | 135.2 | 118.9 | 44.7 | +13.71% |
| Accounts receivable changes | (120.3) | (117.1) | (60.2) | +2.73% |
| Inventories changes | (46.0) | (59.3) | (105.4) | -22.43% |
| Other assets changes | (74.5) | (132.5) | (89.4) | -43.77% |
| Operating lease right-of-use assets and liabilities changes | (46.8) | (42.4) | (34.2) | +10.38% |
| Accounts payable changes | 8.0 | 9.3 | 5.5 | -13.98% |
| Accrued liabilities changes | 27.9 | 3.6 | 71.8 | +675.00% |
| Accrued income taxes changes | (51.7) | (15.4) | (0.5) | +235.71% |
| Other long-term liabilities changes | 18.6 | 20.1 | (6.4) | -7.46% |
| Net cash provided by operating activities | 796.1 | 709.3 | 607.5 | +12.24% |
| Purchases of property, plant and equipment | (362.4) | (421.2) | (392.5) | -13.96% |
| Acquisitions of businesses and assets, net of cash acquired, and other | (10.5) | (343.4) | (56.5) | -96.94% |
| Net cash used in investing activities | (372.9) | (764.6) | (449.0) | -51.23% |
| Proceeds from long-term debt, net of issuance costs | 3,111.1 | 3,524.2 | 2,124.2 | -11.72% |
| Repayments of long-term debt | (3,205.2) | (3,506.8) | (1,953.9) | -8.60% |
| Net proceeds from (repayments of) short-term debt, other | 14.2 | (11.8) | (351.1) | N/M |
| Repurchase of common stock | (290.1) | — | — | N/M |
| Proceeds related to share-based compensation awards | 5.4 | 55.6 | 15.1 | -90.29% |
| Payments related to share-based compensation awards | (24.8) | (30.3) | (13.1) | -18.15% |
| Dividends on common stock | — | — | (3.0) | N/M |
| Issuance of common stock for employee stock purchase plan | 10.6 | 8.3 | 7.9 | +27.71% |
| Acquisition installment payment | (47.1) | — | — | N/M |
| Net cash provided (used in) by financing activities | (425.9) | 39.2 | (173.9) | N/M |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 5.6 | 2.9 | (2.3) | +93.10% |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 2.9 | (13.2) | (17.7) | N/M |
Net cash provided by operating activities increased to $796.1 million in fiscal 2025, up from $709.3 million in fiscal 2024 and $607.5 million in fiscal 2023, demonstrating strong cash generation from underlying operations and effective working capital management.
Funding the Future: R&D and Expansion Spending
Research and development expenses totaled $172.2 million in fiscal 2025, compared to $155.1 million in fiscal 2024 and $137.4 million in fiscal 2023, reflecting continuous investments in next-generation contact lens designs, manufacturing automation, surgical devices, and fertility solutions. Capital expenditures for property, plant, and equipment remained a key priority at $362.4 million in fiscal 2025, $421.2 million in fiscal 2024, and $392.5 million in fiscal 2023, supporting global manufacturing capacity expansions and enterprise resource planning (ERP) system upgrades.
4. The Corporate Family Tree: The Cooper Companies, Inc. Subsidiaries & Acquisitions
Subsidiaries, Associates, & Shared Ventures
The enterprise conducts its global operations through numerous operating entities and wholly-owned subsidiaries, including CooperVision International Limited, CooperSurgical Netherlands B.V., and CooperVision Holding Kft. These entities coordinate local manufacturing, regulatory filings, and commercial distribution across international jurisdictions.
Strategic Investments & Minority Stakes
Management selectively participates in strategic joint ventures, minority equity investments, and licensing agreements to secure early access to emerging diagnostic technologies, proprietary biomaterials, and specialized distribution channels.
5. Power & Control: The Cooper Companies, Inc. Executive Leadership & Ownership
The Brain Trust: Board of Directors & Executive Leadership
The executive leadership team is spearheaded by Al White, President and Chief Executive Officer, and Brian Andrews, Executive Vice President and Chief Financial Officer, alongside experienced segment presidents and functional leaders. Detailed biographies, board committee memberships, corporate governance principles, and executive compensation tables are incorporated by reference to the Company’s definitive Proxy Statement for the Annual Meeting of Stockholders.
Who Owns the Stock?
Detailed information regarding beneficial ownership of common stock by directors, executive officers, and principal institutional shareholders holding 5% or more of the voting securities is incorporated by reference to the Company’s proxy statement.
6. Strategic Outlook: The Cooper Companies, Inc. Growth Catalysts & Key Risks
Competitive Advantages & Economic Moats
The Cooper Companies maintains formidable competitive advantages, including proprietary silicone hydrogel manufacturing expertise (such as Aquaform technology), exclusive regulatory approvals for myopia progression control (MiSight 1 day across major global markets), a highly diversified portfolio of market-leading fertility and surgical solutions, and deep, enduring relationships with eye care practitioners, hospitals, and fertility clinic networks worldwide.
What Could Go Wrong? Key Challenges & Business Risks
The business faces significant risks and uncertainties, including adverse global macroeconomic conditions, recessionary pressures, inflation, and foreign exchange rate volatility. International operations are exposed to geopolitical instability, international conflicts, and complex trade compliance requirements, including customs duties, trade embargoes, and tariffs. Supply chain vulnerabilities—particularly sole-sourced raw materials used in silicone hydrogel lenses—pose potential manufacturing disruption risks. Furthermore, the Company operates in a highly regulated medical device and healthcare environment subject to rigorous FDA, EU MDR, EU IVDR, and international regulations, unannounced quality inspections, product recalls, pricing pressures from customer consolidation, cybersecurity threats, and potential intellectual property or product liability litigation.
The Next Chapter: Growth & Expansion Initiatives
Strategic growth initiatives focus on driving global market penetration of recently introduced products, expanding manufacturing capacity and efficiency, scaling myopia management education and commercialization, and pursuing disciplined, accretive acquisitions within the vision, fertility, and women’s health sectors.
The Verdict: Strategic Outlook & Conclusion
The Cooper Companies demonstrates durable financial performance, robust operating cash flow generation, and undisputed leadership across vital healthcare niches. Management’s rigorous focus on operational execution, technological innovation, and strategic capital allocation positions the organization for sustained long-term value creation.
❓ Frequently Asked Questions: The Cooper Companies, Inc.
What was The Cooper Companies, Inc.’s revenue and net income in FY 2025?
In FY 2025 Ended Oct 31, 2025, The Cooper Companies, Inc. reported total revenue of $4.09 B (▲ 5.1% compared to $3.90 B in the prior fiscal year). Gross profit stood at $2.68 B (gross margin of 65.54 %). Operating profit was $682.90 M and bottom-line net income was $374.90 M.
Is The Cooper Companies, Inc. profitable and generating positive cash flow in FY 2025?
Yes, The Cooper Companies, Inc. was profitable in FY 2025, recording net profit of $374.90 M (PAT margin: 9.16 %). On a cash basis, the company generated $796.10 M in cash flow from operating activities and invested $362.40 M in capital expenditures, resulting in free cash flow of $433.70 M. Return on Equity (ROE) was 4.55 % and Cash ROE was 9.66 %.
How much debt, assets, and equity does The Cooper Companies, Inc. hold?
As of FY 2025 Ended Oct 31, 2025, The Cooper Companies, Inc. held $12.39 B in total assets, $4.16 B in total liabilities, and $8.24 B in total stockholders’ equity. Total debt stood at $2.51 B (debt-to-equity ratio of 0.30x). Net working capital was $993.60 M with a current ratio of 1.89x.
Who is the CEO and CFO of The Cooper Companies, Inc.?
The Chief Executive Officer (CEO) of The Cooper Companies, Inc. is Al White (President and Chief Executive Officer). The Chief Financial Officer (CFO) is Brian Andrews (Executive Vice President and Chief Financial Officer).
Where is The Cooper Companies, Inc. headquartered and when was it founded?
The Cooper Companies, Inc. is headquartered in 6101 Bollinger Canyon Road, Suite 500, San Ramon, California 94583. The company traces its founding/incorporation to 1990 (CooperSurgical inception) / Incorporated in Delaware. Total disclosed workforce/headcount is More than 15,000 employees globally (52% Americas, 42% EMEA, 6% Asia Pacific). Its official corporate website is https://www.coopercos.com.
Note: Financial ratios, margins, year-over-year (YoY) growth rates, and percentage shares of revenue are calculated by FirmsWorld based on figures reported in the company’s official SEC filing.